Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Clinical Rheumatology

Volumn 32, Issue 11, 2013, Pages 1677-1681

  Besada, Emilio ^a,c   Nossent, Johannes C ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

ANCA associated vasculitis; Chemoprophylaxis; Granulomatosis with polyangiitis; Pneumocystis jiroveci pneumopathy; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADULT; ANCA ASSOCIATED VASCULITIS; ANTIBIOTIC THERAPY; AUTOIMMUNE DISEASE; BRONCHOSCOPY; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FUNGAL COLONIZATION; FUNGAL STRAIN; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LABORATORY TEST; MALE; MONOTHERAPY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SEROLOGY; SYMPTOM; TREATMENT DURATION;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS;

EID: 84886308944     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2293-4     Document Type: Review

References (34)

1. Ward M, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases. The role of the experience in diagnosis and mortality. Arthritis Rheum 42:780-9 (Pubitemid 29172000)
2. Sepkowitz KA (2002) Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 34:1098-107 (Pubitemid 34289683)
3. Martin-Garrido I, Carmona EM, Specks U et al (2012) Pneumocystis pneumonia in patients treated with rituximab. Chest. doi: 10.1378/chest.12-0477
4. Ognibene FP, Shelhammer JH, Hoffman GS et al (1995) Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 151:795-9
5. Guillevin L, Cordier JF, Lhote F et al (1997) A prospective multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40:2187-98 (Pubitemid 28016415)
6. Green H, Paul M, Vidal L et al (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomised controlled trials. Mayo Clin Proc 82:1052-9 (Pubitemid 47357136)
7. Suryaprasad A, Stone JH (2008) When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 59:1034-9 (Pubitemid 351991002)
8. Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of primary small and medium vessels vasculitis. Ann Rheum Dis 68:310-7
9. Jones RB, Cohen Tevaert JW, Hauser T et al (2010) Randomized trial of rituximab versus cyclophosphamide in ANCA-associated renal vasculitis 'RITUXVAS'. N Engl J Med 363:211-20
10. Stone JH, Merkel PA, Seo P et al (2010) Rituximab versus cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE). N Engl J Med 363:221-32
11. Rhee EP, Laliberte KA, Niles JL (2010) Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 5:1394-1400
12. Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N et al (2012) Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 39:125-30
13. Smith RM, Jones RB, Guerry MJ et al (2012) Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 64:3760-69
14. Cartin-Ceba R, Golbin JM, Keogh KA et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 64:3770-8
15. Mori S, Sugimoto M (2012) Pneumocystis jiroveci infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology. doi: 10.1093/rheumatology/kes244
16. Mekinian A, Durand-Joly I, Hatron PY et al (2011) Pneumocystis jiroveci colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology 50:569-77
17. Fritzsche C, Riebold D, Munk-Hartig AK et al (2012) High prevalence of Pneumocystis jiroveci colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol 41:208-13
18. Mori S, Cho I, Sugimoto M (2010) A cluster of Pneumocystis jiroveci infection among outpatients with rheumatoid arthritis. J Rheumatol 37:1547-8
19. Mori S, Cho I, Sugimoto M (2009) Follow-up study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 36:1600-5
20. Lund FE, Hollifield M, Schuer K et al (2006) B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 176:6147-54
21. Kamel S, O'Connor S, Lee N et al (2010) High incidence of Pneumocystis jiroveci pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine and prednisolone. Leuk Lymphoma 51:797-801
22. Kim T, Choi SH, Kim SH et al (2012) Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. Ann Hematol. doi: 10.1007/s00277-012-1592-1
23. Hashimoto K, Kobayashi Y, Asakura Y et al (2010) Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count with B cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 51:1816-21
24. Katsuya H, Suzumiya J, Sasaki H et al (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50:1818-23
25. Kolstad A, Holte H, Fosså A et al (2007) Pneumocystis jiroveci pneumonia in B cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92:139-40 (Pubitemid 46232678)
26. Venhuizen AC, Hustinx WN, van Houte AJ et al (2007) Three cases of Pneumocystis jiroveci pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B cell non-Hodgkin's lymphoma. Eur J Haematol 80:275-6 (Pubitemid 351253467)
27. Fishman JA, Rubin RH (1998) Infection in organ-transplant recipient. N Engl J Med 338:1741-51 (Pubitemid 28268592)
28. Shelton E, Yong M, Cohney S (2009) Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 14:696-9
29. Holle JU, Dubrau C, Herlyn K et al (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 71:327-33
30. Roll P, Ostermeier E, Haubitz M et al (2012) Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German Registry (GRAID). J Rheumatol. doi: 10.3899/jrheum.120482
31. Pullerits R, Ljevakt M, Vikgren J et al (2012) Off-trial evaluation of the B cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol 76:411-20
32. Wendt M, Gunnarson I, Bratt J et al (2012) Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol 41:116-9
33. Specks U (2012) Biologic agents in the treatment of granulomatosis with polyangiitis. Cleve Clin J Med 79(supplement 3):S50-53
34. Stamp LK, Hurst M (2010) Is there a role for consensus guidelines for P. jiroveci prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol 37:686-8